PPAR-γ agonists of the thiazolidinediones (TZDs) class, like rosiglitazone, are currently used to treat type-2 diabetes mellitus patients, mainly due to their insulin-sensitizing effects. This evidence concerns the gene PPARG and type 2 diabetes mellitus.